D
Danijela Maksimović-Ivanić
Researcher at University of Belgrade
Publications - 120
Citations - 4723
Danijela Maksimović-Ivanić is an academic researcher from University of Belgrade. The author has contributed to research in topics: Apoptosis & In vivo. The author has an hindex of 32, co-authored 102 publications receiving 4138 citations. Previous affiliations of Danijela Maksimović-Ivanić include University of Bologna.
Papers
More filters
Journal ArticleDOI
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
Linda S. Steelman,William H. Chappell,Stephen L. Abrams,C. Ruth Kempf,Jacquelyn M. Long,Piotr Laidler,Sanja Mijatović,Danijela Maksimović-Ivanić,Franca Stivala,Maria Clorinda Mazzarino,Marco Donia,Paolo Fagone,Graziella Malaponte,Ferdinando Nicoletti,Massimo Libra,Michele Milella,Agostino Tafuri,Antonio Bonati,Jörg Bäsecke,Lucio Cocco,Camilla Evangelisti,Alberto M. Martelli,Giuseppe Montalto,Melchiorre Cervello,James A. McCubrey +24 more
TL;DR: The functions these pathways have in normal and neoplastic tissue growth and how they contribute to resistance to apoptotic stimuli are discussed and the recently described roles of these pathways in cancer stem cells, cellular senescence and aging are evaluated.
Journal ArticleDOI
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
William H. Chappell,Linda S. Steelman,Jacquelyn M. Long,Ruth C. Kempf,Stephen L. Abrams,Richard A. Franklin,Jörg Bäsecke,Franca Stivala,Marco Donia,Paolo Fagone,Graziella Malaponte,Maria Clorinda Mazzarino,Ferdinando Nicoletti,Massimo Libra,Danijela Maksimović-Ivanić,Sanja Mijatović,Giuseppe Montalto,Melchiorre Cervello,Piotr Laidler,Michele Milella,Agostino Tafuri,Antonio Bonati,Camilla Evangelisti,Lucio Cocco,Alberto M. Martelli,James A. McCubrey +25 more
TL;DR: This review will evaluate more recently described potential uses of MEK, PI3K, Akt and mTOR inhibitors in the proliferation of malignant cells, suppression of CICs, cellular senescence and prevention of aging.
Journal ArticleDOI
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
James A. McCubrey,Linda S. Steelman,William H. Chappell,Stephen L. Abrams,Richard A. Franklin,Giuseppe Montalto,Melchiorre Cervello,Massimo Libra,Saverio Candido,Grazia Malaponte,Maria Clorinda Mazzarino,Paolo Fagone,Ferdinando Nicoletti,Jörg Bäsecke,Sanja Mijatović,Danijela Maksimović-Ivanić,Michele Milella,Agostino Tafuri,Francesca Chiarini,Camilla Evangelisti,Lucio Cocco,Alberto M. Martelli +21 more
TL;DR: How cancers can become insensitive to various inhibitors and potential strategies to overcome this resistance are discussed.
Journal ArticleDOI
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mtor cascades which alter therapy response
James A. McCubrey,Linda S. Steelman,William H. Chappell,Stephen L. Abrams,Giuseppe Montalto,Melchiorre Cervello,Ferdinando Nicoletti,Paolo Fagone,Grazia Malaponte,Maria Clorinda Mazzarino,Saverio Candido,Massimo Libra,Jörg Bäsecke,Sanja Mijatović,Danijela Maksimović-Ivanić,Michele Milella,Agostino Tafuri,Lucio Cocco,Camilla Evangelisti,Francesca Chiarini,Alberto M. Martelli +20 more
TL;DR: The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are described and how genetic mutations and epigenetic alterations can result in resistance to various inhibitors are discussed.
Journal ArticleDOI
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention
Nicole Marie Davis,Melissa L. Sokolosky,Kristin Stadelman,Stephen L. Abrams,Massimo Libra,Saverio Candido,Ferdinando Nicoletti,Jerry Polesel,Roberta Maestro,Antonino B. D'Assoro,Lyudmyla Drobot,Dariusz Rakus,Agnieszka Gizak,Piotr Laidler,Joanna Dulińska-Litewka,Jörg Bäsecke,Sanja Mijatović,Danijela Maksimović-Ivanić,Giuseppe Montalto,Melchiorre Cervello,Timothy L. Fitzgerald,Zoya N. Demidenko,Alberto M. Martelli,Lucio Cocco,Linda S. Steelman,James A. McCubrey +25 more
TL;DR: The targeting of the hormone receptor, HER2 and EGFR1 in breast cancer will be reviewed in association with suppression of the EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway.